1. A network printing method comprising:
providing a plurality of output printing devices coupled to the network, each output printing device comprising status information;
providing a client computer coupled to the network; and
providing an application adapted to run on the client computer, wherein the application is adapted to submit a first print job to a first output printing device and a second print job to a second output printing device, receive the status information regarding the output printing devices, determine which of the received status information is relevant to the first and second print jobs, filter the status information to extract the status information relevant to the first and second print jobs, and group and display the filtered status information regarding the first and second output printing devices.
2. The printing method of claim 1, wherein the output printing devices comprise a printer.
3. The printing method of claim 1, wherein the output printing devices comprise a copier.
4. The printing method of claim 1, wherein the status information comprises paper input tray information.
5. The printing method of claim 1, wherein the status information comprises toner level information.
6. The printing method of claim 1, wherein the status information comprises fuser level information.
7. The printing method of claim 1, wherein the status information comprises paper output tray information.
8. The printing method of claim 1, wherein the status information comprises output printing device service information.
9. A network printing method comprising:
providing a plurality of output printing devices coupled to the network, each output printing device comprising status information;
providing a client computer coupled to the network; and
submitting a first print job from the client computer to a first output printing device and a second print job to a second output printing device;
receiving at the client computer the status information regarding the output printing devices;
determining at the client computer which of the received status information is relevant to the first and second print jobs;
filtering the status information at the client computer to extract the status information relevant to the first and second print jobs; and
grouping and displaying on the client computer the filtered status information regarding the first and second output printing devices.
10. The printing method of claim 9, wherein the output printing devices comprise a printer.
11. The printing method of claim 9, wherein the output printing devices comprise a copier.
12. The printing method of claim 9, wherein the status information comprises paper input tray information.
13. The printing method of claim 9, wherein the status information comprises toner level information.
14. The printing method of claim 9, wherein the status information comprises fuser level information.
15. The printing method of claim 9, wherein the status information comprises paper output tray information.
16. The printing method of claim 9, wherein the status information comprises output printing device service information.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A system for treating blood or plasma from a mammal, the system comprising an extracorporeal bioreactor (EB) comprising a fluid treatment compartment and a cell compartment, and a selectively permeable barrier separating the fluid treatment compartment and the cell compartment, wherein the cell compartment comprises a population of undifferentiated multipotent stromal cells (MSCs).
2. The system of claim 1, wherein the cell compartment further comprises a population of primary hepatocytes.
3. The system of claim 1, wherein the selectively permeable barrier comprises a bundle of hollow fibers.
4. The system of claim 1, wherein the EB further comprises a biological fluid inlet and a biological fluid outlet, wherein the biological fluid inlet and outlet permit fluid communication between the fluid treatment compartment and a bloodstream of the mammal.
5. The system of claim 1, further comprising a plurality of pumps for circulating the blood or plasma through the fluid treatment compartment.
6. The system of claim 1, the system further comprising an ultrafiltration cartridge in fluid communication with the fluid treatment compartment.
7. A method of treating liver disease in a subject, the method comprising:
(a) identifying a subject having a liver disease;
(b) providing a system for treating blood or plasma from a mammal, the system comprising an extracorporeal bioreactor (EB) comprising a fluid treatment compartment and a cell compartment, and a selectively permeable barrier separating the fluid treatment compartment and the cell compartment, wherein the cell compartment comprises a population of undifferentiated multipotent stromal cells (MSCs); and
(c) exposing the subject’s plasma or blood to the MSCs in the EB.
8. The method of claim 7, wherein the subject is identified by evaluating the level of a serum marker of liver function.
9. The method of claim 8, wherein the serum marker of liver function is selected from the group consisting of lactate dehydrogenase (LDH), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum bilirubin, albumin and globulins.
10. The method of claim 7, wherein the EB further comprises a population of primary hepatocytes.
11. A method for treating blood or plasma from a subject having a liver disease, the method comprising:
(a) identifying a subject having a liver disease;
(b) providing a system comprising an extracorporeal bioreactor (EB) comprising a fluid treatment compartment and a cell compartment, and a selectively permeable barrier separating the fluid treatment compartment and the cell compartment, wherein the cell compartment comprises a population of undifferentiated multipotent stromal cells (MSCs);
(c) removing blood or plasma from the subject;
(d) introducing the blood or plasma into the fluid treatment compartment of the EB; and
(e) allowing the blood or plasma to flow through and exit the fluid treatment compartment,
thereby treating the blood or plasma.
12. The method of claim 11, wherein the subject is identified by evaluating the level of a serum marker of liver function.
13. The method of claim 12, wherein the serum marker of liver function is selected from the group consisting of lactate dehydrogenase (LDH), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum bilirubin, albumin and globulins.
14. The method of claim 12, wherein the EB further comprises a population of primary hepatocytes.
15. A method of preparing a composition for the treatment of liver disease, the method comprising:
(i) obtaining a population of undifferentiated multipotent stromal cells (MSCs);
(ii) culturing the MSCs in a medium;
(iii) obtaining the medium;
(iv) fractionating the medium;
(v) selecting a fraction of the medium that is capable of one or both of promoting hepatocyte proliferation or inhibiting hepatocyte death; and
(vi) optionally, formulating the selected fraction for administration to a mammal.
16. The method of claim 15, wherein the composition is concentrated 25-fold.
17. The method of claim 16, wherein the medium comprises a serum free tissue culture medium or phosphate buffered saline (PBS).
18. The method of claim 15, further comprising lyophilizing the composition.
19. A composition provided by the method of claim 15.
20. A method of treating liver disease in a subject, the method comprising identifying a subject in need of treatment, and administering to the subject an effective amount of a composition comprising MSC-conditioned media (MSC-CM).
21. The method of claim 20, wherein the subject is identified by evaluating the level of a serum marker of liver function.
22. The method of claim 21, wherein the serum marker of liver function is selected from the group consisting of lactate dehydrogenase (LDH), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), serum bilirubin, albumin and globulins.
23. The method of claim 21, wherein treatment continues until the subject’s level of a serum marker of liver function is within the normal range as determined by the subject’s clinician.
24. The method of claim 21, wherein the liver disease to be treated is acute liver failure, fulminant hepatic failure, or liver fibrosis.
25. The method of claim 21, wherein the composition is administered using an intravenous bolus technique.
26. The method of claim 21, wherein the MSC-CM is obtained by a method comprising:
(a) obtaining a population of undifferentiated multipotent stromal cells (MSCs);
(b) culturing the MSCs in a medium;
(c) obtaining the medium;
(d) optionally, formulating the selected fraction for administration to the subject.
27. The method of claim 21, wherein the MSC-CM is obtained by a method comprising:
(a) obtaining a population of undifferentiated multipotent stromal cells (MSCs);
(b) culturing the MSCs in a medium;
(c) obtaining the medium;
(d) fractionating the medium;
(e) selecting a fraction of the medium that is capable of one or both of promoting hepatocyte proliferation and inhibiting hepatocyte death; and
(f) optionally, formulating the selected fraction for administration to the subject.
28. A method for identifying a biologically active compound for the treatment of a liver disease, the method comprising;
(a) obtaining one or more fractions of a medium containing factors secreted from a population of undifferentiated multipotent stromal cells (MSCs);
(b) assaying the ability of one or more of the fractions to promote one or both of hepatocyte proliferation or inhibit hepatocyte death;
(c) selecting a fraction of the medium that promotes one or both of hepatocyte proliferation or inhibit hepatocyte death; and
(d) identifying one or more molecules present in the selected fraction.
29. The method of claim 28, wherein the fractions are obtained according to size.
30. The method of claim 28, wherein the fractions are obtained according to charge.
31. The method of claim 28, wherein the fraction of the medium is a heparin sulfate binding fraction of the medium.